Evercore ISI Group Maintains In-Line on eBay, Lowers Price Target to $50
Evercore ISI Group analyst Mark Mahaney maintains eBay (NASDAQ:EBAY) with a In-Line and lowers the price target from $59 to $50.
Evercore ISI Group Maintains Outperform on Booking Holdings, Lowers Price Target to $2600
Evercore ISI Group analyst Mark Mahaney maintains Booking Holdings (NASDAQ:BKNG) with a Outperform and lowers the price target from $3000 to $2600.
Health Advance Starts Production Of Its CBD Infused De-Alcoholized Wine Beverage
Health Advance, Inc.’s (OTCPK:HADV) new CBD infused de-alcoholized wine beverage is now in production. Allocation of the first manufacturing run of 19,400 units will be made among customers who are competing for early deliveries at the beginning of August.
Kevin O’Leary: Why Bitcoin’s Crash, Voyager Collapse Are ‘Good Thing’ For Crypto
All the liquidation and bankruptcy events that followed the Bitcoin (CRYPTO: BTC) market downturn will prove to be healthy for the crypto market in the long run, according to Shark Tank investor Kevin O’Leary.
Lake Street Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target from $14 to $8.
Craig-Hallum Maintains Buy on Aspen Aerogels, Lowers Price Target to $32
Craig-Hallum analyst Eric Stine maintains Aspen Aerogels (NYSE:ASPN) with a Buy and lowers the price target from $50 to $32.
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,500 Today
Keysight Technologies (NYSE:KEYS) has outperformed the market over the past 5 years by 18.87% on an annualized basis producing an average annual return of 28.7%. Currently, Keysight Technologies has a market capitalization of $25.63 billion.
Cowen & Co. Maintains Outperform on Caterpillar, Lowers Price Target to $225
Cowen & Co. analyst Matt Elkott maintains Caterpillar (NYSE:CAT) with a Outperform and lowers the price target from $255 to $225.
The Daily Biotech Pulse: Merck’s Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours: